Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367871 · ClinicalTrials.gov registry record · Phase 2
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
A Phase 2 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03367871 is a Phase 2 study that was terminated before completion, run by University of Miami. The registered enrollment target is 17 participants.
The verdict
NCT03367871, a Phase 2 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
Interventions
- DRUG Pembrolizumab
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367871
The ClinicalTrials.gov registry entry for NCT03367871 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03367871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03367871 about?
NCT03367871 is a clinical study titled "Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer". The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
What is the current status of trial NCT03367871?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2018-09-06. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT03367871?
The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03367871?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.